mdl-100907 and Cardiovascular-Diseases

mdl-100907 has been researched along with Cardiovascular-Diseases* in 3 studies

Reviews

2 review(s) available for mdl-100907 and Cardiovascular-Diseases

ArticleYear
Therapeutic potentials of sarpogrelate in cardiovascular disease.
    Cardiovascular drug reviews, 2004,Spring, Volume: 22, Issue:1

    In view of the pivotal role of serotonin (5-HT) in a wide variety of cardiovascular disorders, extensive effort has been made to develop different types of 5-HT receptor antagonists for therapeutic use. On the basis of experimental studies, this article is focused on the potentials of sarpogrelate, a specific 5-HT2A receptor antagonist as an antiplatelet, antithrombotic, antiatherosclerotic and antianginal agent. The major effects of sarpogrelate are due to the inhibition of 5-HT-induced platelet aggregation and smooth muscle cell proliferation. This agent was found to attenuate the 5-HT-mediated increase in intracellular Ca2+ and ischemia-reperfusion injury in the heart. Sarpogrelate has been found to have beneficial effects in peripheral vascular disease, restenosis after coronary stenting, pulmonary hypertension, acute and chronic myocardial infarction.

    Topics: Animals; Cardiovascular Diseases; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Serotonin 5-HT2 Receptor Antagonists; Succinates

2004
Functions of 5-HT2A receptor and its antagonists in the cardiovascular system.
    Pharmacology & therapeutics, 2004, Volume: 104, Issue:1

    The serotonin (5-hydroxytryptamine, 5-HT) receptors have conventionally been divided into seven subfamilies, most of which have several subtypes. Among them, 5-HT(2A) receptor is associated with the contraction of vascular smooth muscle, platelet aggregation and thrombus formation and coronary artery spasms. Accordingly, selective 5-HT(2A) antagonists may have potential in the treatment of cardiovascular diseases. Sarpogrelate, a selective 5-HT(2A) antagonist, has been introduced clinically as a therapeutic agent for the treatment of ischemic diseases associated with thrombosis. Molecular modeling studies also suggest that sarpogrelate is a 5-HT(2A) selective antagonist and is likely to have pharmacological effects beneficial in the treatment of cardiovascular diseases. This review describes the above findings as well as the signaling linkages of the 5-HT(2A) receptors and the mode of agonist binding to 5-HT(2A) receptor using data derived from molecular modeling and site-directed mutagenesis.

    Topics: Animals; Cardiovascular Diseases; Cardiovascular System; Humans; Protein Binding; Receptor, Serotonin, 5-HT2A; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists

2004

Other Studies

1 other study(ies) available for mdl-100907 and Cardiovascular-Diseases

ArticleYear
Exploring the antiplatelet activity of serotonin 5-HT
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 145

    Small drug-like molecules that can block the function of serotonin 5-HT

    Topics: Animals; Cardiovascular Diseases; Humans; Isoxazoles; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Serotonin 5-HT2 Receptor Antagonists; Structure-Activity Relationship; Succinates; Vasoconstriction

2022